Oral BPC 157 Restores Platelet Aggregation Inhibited by Aspirin, Clopidogrel, and Cilostazol
Background
Antithrombotic agents like aspirin, clopidogrel, and cilostazol are crucial for preventing blood clots but carry a significant risk of impaired platelet function, leading to bleeding complications. These drugs work by inhibiting key pathways in platelet aggregation, such as those mediated by arachidonic acid and ADP. A major challenge is mitigating these side effects without compromising the therapeutic anti-clotting benefits. The stable gastric pentadecapeptide BPC 157 is being investigated as a potential agent that might rescue thrombocyte function, offering a novel approach to protect against the adverse effects of these widely used medications.
Study Design
Rats were treated intragastrically once daily for three days with one of three antithrombotic agents: aspirin (10 mg/kg), clopidogrel (10 mg/kg), or cilostazol (10 mg/kg). Immediately after each dose, a separate group received either the peptide BPC 157 (10 µg/kg) or saline (5 ml/kg) as a control, also via intragastric application. Blood samples were collected 2 hours after the final treatment. Platelet function was assessed using multiple electrode aggregometry with various agonists, and blood clot properties were analyzed via modified rotational thromboelastometry.
Results
BPC 157 effectively counteracted the inhibitory effects of all three antithrombotic drugs on platelet aggregation. Specifically, BPC 157 restored aggregation induced by arachidonic acid in rats treated with aspirin, clopidogrel, and cilostazol. It also rescued ADP-induced aggregation in the clopidogrel group and collagen-induced aggregation in the clopidogrel group. For rats on cilostazol, BPC 157 reversed the inhibition of aggregation caused by arachidonic acid/PGE1.
Notably, while BPC 157 rescued thrombocyte function, it had no effect on the intrinsic or extrinsic hemostasis systems or the fibrin part of the clot, as measured by
EXTEM,INTEM, andFIBTEMtests. Key parameters like clotting time, clot formation time, alpha-angle, maximum clot firmness, and lysis index remained unchanged, suggesting a specific action on platelets without altering the broader coagulation cascade.
Key Findings
- BPC 157 (10 µg/kg, oral) counteracted the inhibitory effects of aspirin (10 mg/kg) on arachidonic acid-induced platelet aggregation.
- BPC 157 rescued platelet aggregation inhibited by clopidogrel (10 mg/kg), specifically for ADP and collagen-induced pathways.
- When co-administered with cilostazol (10 mg/kg), BPC 157 restored aggregation induced by both arachidonic acid and arachidonic acid/PGE1.
- BPC 157 did not affect standard thromboelastometry parameters (
EXTEM,INTEM,FIBTEM), suggesting no impact on the broader coagulation cascade. - The study demonstrates that oral BPC 157 can largely rescue thrombocyte function from inhibition by various antithrombotic agents.
Why It Matters
The findings suggest BPC 157 may have a protective role for individuals on common antiplatelet therapies, potentially mitigating bleeding risks by restoring normal thrombocyte function without negating the drugs' primary antithrombotic purpose. For peptide users, this highlights a specific, targeted mechanism for BPC 157 in hematological homeostasis. From a clinical perspective, this is a very early-stage animal study, and human trials are needed to confirm safety and efficacy. The key takeaway is that BPC 157 could potentially be co-administered with antiplatelet drugs to normalize platelet response, but it does not appear to interfere with the overall clotting process measured by thromboelastometry. This specific action on aggregation without affecting the coagulation cascade is a significant finding.
TitrateLab articles covering BPC-157
Written by TitrateLab, separately from the study summarized above.
bpc-157
aspirin
clopidogrel
cilostazol
platelet aggregation
thrombocyte function